Form 8-K

8-K — Humacyte, Inc.

Accession: 0001104659-26-048164

Filed: 2026-04-24

Period: 2026-04-21

CIK: 0001818382

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Entry into a Material Definitive Agreement

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2612631d1_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (tm2612631d1_ex10-1.htm)

EX-99.1 — EXHIBIT 99.1 (tm2612631d1_ex99-1.htm)

GRAPHIC (tm2612631d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2612631d1_8k.htm · Sequence: 1

false

0001818382

2026-04-21

0001818382

us-gaap:CommonStockMember

2026-04-21

0001818382

HUMA:RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member

2026-04-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange

Act of 1934

Date of Report (Date of earliest event reported):

April 21, 2026

Humacyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39532

85-1763759

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

2525 East North Carolina Highway 54

Durham, NC

27713

(Address of principal executive offices)

(Zip code)

(919) 313-9633

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common

Stock, par value $0.0001 per share

HUMA

The Nasdaq Stock Market LLC

Redeemable

Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

HUMAW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period

for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

On April 21, 2026, Humacyte, Inc. (the “Company”) entered

into the Third Amendment to Distribution Agreement (the “Amendment”) with Fresenius Medical Care Holdings, Inc. (“Fresenius”),

to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius (the “Agreement”).

Under the Agreement, Humacyte granted to Fresenius rights to develop and commercialize the Company’s 6 millimeter acellular tissue

engineered vessel-tyod (the “Distribution Product”) outside of the U.S. As a result of the Amendment, the Company has the

sole right to develop and commercialize, and conduct all regulatory matters relating to, the Distribution Product on a worldwide basis.

Additionally, the Company will pay to Fresenius low-single-digit royalties on net sales of the Distribution Product in connection with

this reversion of ex-U.S. rights to the Company under the Amendment subject to a two-year royalty free period following launch of the

Distribution Product in each applicable country, The Company will continue to pay royalties on net sales of the Distribution Product in

the U.S. at rates ranging from mid-single digits to low double digits and Fresenius remains obligated to adopt the Distribution Product

as a standard of care in hemodialysis patients for which such use is supported by clinical results and health economic analyses..

The description of the Amendment set forth above is only a summary

of its material terms and does not purport to be complete, and is qualified in its entirety by reference to the full and complete terms

contained in the Amendment, which is filed as Exhibit 10.1 to this Form 8-K and is incorporated into this Item 1.01 by reference. The

Amendment is not intended to be a source of factual, business or operational information about the Company or its subsidiaries. The representations,

warranties and covenants contained in the Amendment were made only for purposes of the Amendment and as of specific dates, were solely

for the benefit of the parties to the Amendment, and may be subject to limitations agreed upon by the parties, including being qualified

by disclosures for the purpose of allocating contractual risk between the parties instead of establishing matters as facts; and may be

subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors or security holders.

Accordingly, investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations

of the actual state of facts or condition of the parties.

Item 7.01. Regulation FD Disclosure

On April 24, 2026, the Company issued a press release

announcing the entry into the Amendment. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and

is incorporated herein by reference.

The information in this Item 7.01 is being furnished

and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise

subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration

statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

10.1*

Third Amendment to Distribution Agreement, dated as of April 21, 2026, between Humacyte, Inc. and Fresenius Medical Care Holdings, Inc.

99.1

Press release, dated April 24, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Certain confidential information contained in this

exhibit, market by brackets, has been omitted because the information (i) is not material and (ii) is the type of information the company

both customarily and actually treats as private or confidential.

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMACYTE, INC.

Date: April 24, 2026

By:

/s/

Dale A. Sander

Name:

Dale

A. Sander

Title:

Chief

Financial Officer, Chief Corporate Development Officer and Treasurer

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2612631d1_ex10-1.htm · Sequence: 2

Exhibit 10.1

Certain identified information has been excluded from this exhibit

because such information both (i) is not material and (ii) is the type that the registrant both customarily and actually treats

as private or confidential. Excluded information is indicated with brackets and asterisks.

THIRD AMENDMENT TO DISTRIBUTION AGREEMENT

This THIRD AMENDMENT TO DISTRIBUTION AGREEMENT

(this “Third Amendment”), entered into as of April 21, 2026 (the “Third Amendment Date”), and effective

as of the Third Amendment Date, is made and entered into by and between Fresenius Medical Care Holdings, Inc., a corporation organized

and existing under the Laws of the State of New York (“Fresenius”), and Humacyte, Inc., a corporation organized and

existing under the Laws of the State of Delaware (“Humacyte”).

WHEREAS, Fresenius and Humacyte entered into that

certain Distribution Agreement,

effective as of June 25, 2018 (the “Original Agreement”),

as amended by that certain First

Amendment, dated as of October 2, 2019 (the “First Amendment”),

and as amended by that certain Second Amendment, dated as of February 16, 2021 (the “Second Amendment”);

WHEREAS, the term “Agreement” where

used in the Original Agreement and this Third Amendment, is deemed inclusive of the Original Agreement as amended by the First Amendment,

the Second Amendment, and this Third Amendment; and

WHEREAS, Fresenius and Humacyte each wish to amend

and update certain aspects of the Agreement.

NOW, THEREFORE, in consideration of the mutual

covenants and obligations set forth out in this Third Amendment and other good and valuable consideration, the sufficiency of which are

acknowledged, the parties to this Third Amendment agree as follows:

1. Definitions; Cross References.

1.1 All terms not expressly defined or modified in this Third Amendment

shall have

the meaning ascribed therefor in the Agreement.

1.2 Unless otherwise indicated, all references to Sections and Articles

herein are references to the corresponding Section or Article of the Agreement.

2. Certain Agreements and Amendments of the Agreement.

2.1 Section 2 is hereby deleted in its entirety and replaced with “Reserved.”.

2.2 Sections 3.2-3.3 (inclusive) are hereby deleted in their entirety

and replaced with “Reserved.”.

2.3 Sections 4.2-4.6 (inclusive) are hereby deleted in their entirety

and replaced with “Reserved.”.

2.4 Section 5 is hereby deleted in its entirety and replaced with “Reserved.”.

2.5 Section 6 is hereby deleted in its entirety and replaced with “Reserved.”.

2.6 Section 7 is hereby deleted in its entirety and replaced with “Reserved.”.

2.7 Section 8 is hereby deleted in its entirety and replaced with “Reserved.”.

2.8 Section 9 is hereby deleted in its entirety and replaced with “Reserved.”.

2.9 Section 10.1.1 is hereby deleted in its entirety and replaced with

the following:

10.1.1 Royalties to Fresenius. Humacyte will make royalty payments

to Fresenius based on (a) aggregate Net Sales of the Distribution Product in the United States in the Field [***], and (b) aggregate Net

Sales of the Distribution Product in the EU and ROW in the Field [***]with the rates, set forth in the table below.

Time Period

Royalty Rate of Net Sales

Territory

Until such time that Humacyte has paid to Fresenius a total of [***] in royalty payments pursuant to this Section 10.1.1

[***]

Beginning on the Third Amendment Effective Date

[***]

EU and ROW

After Humacyte has paid to Fresenius a total of [***] in royalty payments pursuant to this Section 10.1.1

[***]

Humacyte’s obligation to make royalty payments to Fresenius pursuant

to the first paragraph of this Section 10.1.1 in the EU and ROW for sales in a particular country shall only begin on the third Product

Year for such country (for each such country, the “Holiday Period”). During the Holiday Period, Net Sales in a country

shall exclude [***].

The Parties acknowledge that for purposes of this Section 10.1.1, the

definition of Net Sales shall apply to Humacyte, mutatis mutandis, where, for clarity, (a) the “Selling Parties” for calculating

Net Sales are Humacyte or any of Humacyte’s Related Parties and (b) in the case of any sale or other disposal of a Distribution

Product, in each case, between or among Humacyte and any other Selling Party for resale, Net Sales will be calculated only on the value

charged or invoiced on the first arm’s-length sale thereafter to the first Third Party other than a Related Party by a Selling Party.

All such royalty payments to Fresenius are, in part, consideration

for Fresenius’ activities under the Agreement prior to the Third Amendment Date and are in lieu of any other consideration with

respect to the Commercialization of the Distribution Product and any Additional Products in the US, EU or ROW.

2.10 Section 10.1.2 is hereby deleted in its entirety and replaced

with “Reserved.”.

2.11 Section 10.1.3 is hereby deleted in its entirety and replaced

with “Reserved.”.

2.12 Section 10.1.5 is hereby deleted in its entirety and replaced

with “Reserved.”.

2.13 Section 10.2.2 is hereby deleted in its entirety and replaced

with “Reserved.”.

2.14 Section 11 is hereby deleted in its entirety and replaced with

“Reserved.”.

2.15 Section 12 is hereby deleted in its entirety and replaced with

the following:

12.1 License Grants to

Humacyte. Subject to the terms and conditions of this Agreement, Fresenius hereby grants Humacyte a non-exclusive, non-transferable

(except as provided in Section 18.1), sublicensable (through multiple tiers) license (including a right of reference) under the Fresenius

Technology to Exploit the Distribution Product in the Field anywhere in the world, solely (a) to the extent used in and necessary for

the Exploitation of the Distribution Product on the Third Amendment Date and (b) as the Distribution Product exists on the Third Amendment

Date (it being understood that with respect to any such Fresenius Technology that is in-licensed by Fresenius or any of its Affiliates,

Humacyte will be responsible for any payments due to a Third Party with respect thereto and Humacyte’s rights thereunder will be

subject to the terms and conditions of the applicable Third Party agreement and Humacyte agreeing to be bound thereby).

2.16 Section 14.2 is hereby deleted in its entirety and replaced with

“Reserved.”.

2.17 Section 14.3 is hereby deleted in its entirety and replaced with

“Reserved.”.

2.18 Section 14.4 is hereby deleted in its entirety and replaced with

“Reserved.”.

2.19 Section 14.6 is hereby deleted in its entirety and replaced with

“Reserved.”.

2.20 Sections 16.4-16.10 (inclusive) are hereby deleted in their entirety

and replaced with “Reserved.”.

2.21 The section references in the second sentence of Section 17.8

following the phrase “shall survive expiration or termination of this Agreement for any reason:” are hereby deleted in their

entirety and replaced with the following:

Sections 1, 10.1.1, 10.2.4, 12.1, 13,

15, 16.2.3, 16.3.1, 17.8 and 18.

2.22 Section 18.18 is hereby deleted in its entirety and replaced with

“Reserved.”.

2.23 Schedule 10.1 is hereby deleted in its entirety.

3. Other Provisions.

3.1 Both Parties hereby confirm that the Agreement is in full force

and effect, including

as modified hereby.

3.2 As amended hereby, the Agreement shall remain in full force and

effect.

3.3 This Third Amendment will be construed and the respective rights

of the Parties determined in accordance with the substantive Laws of the State of Delaware, notwithstanding any Laws governing conflicts

of Laws to the contrary.

3.4 As stated in its Code of Ethics and Business Conduct, Fresenius

upholds the values of quality, honesty and integrity, innovation and improvement, respect and dignity, as well as lawful conduct, especially

with regard to anti-bribery and anti-corruption. Fresenius upholds these values in its own operations, as well as in its relationships

with business partners. Fresenius’ continued success and reputation depends on a common commitment to act accordingly. This Third

Amendment has been reviewed by Humacyte and its advisors and Fresenius and its advisors. The parties agree that this Third Amendment is

the product of all their efforts, and that it should not be interpreted in favor of any one party merely because of its efforts in preparing

it, and that both parties are entering into this Third Amendment in good faith.

3.5 The Parties acknowledge and agree that the effect of this Third

Amendment is that Humacyte will have the sole right to Develop, conduct all regulatory matters relating to, and Commercialize the Distribution

Product on a worldwide basis, and that Fresenius will have no obligations to Develop, conduct any regulatory matters relating to, or Commercialize

the Distribution Product. For clarity, the foregoing does not limit Fresenius’s obligations under Section 3.1 of the Agreement.

3.6 Except as expressly set forth in this Third Amendment or the Agreement,

no Person other than the Parties and their respective Affiliates and permitted assignees hereunder will be deemed an intended beneficiary

hereunder or have any right to enforce any obligation of this Third Amendment or the Agreement.

3.7 This Third Amendment may be executed in two or more counterparts,

including by facsimile of PDF signature pages, each of which will be deemed an original, but all of which together will constitute one

and the same instrument.

(Signature page follows)

IN WITNESS WHEREOF, the Parties have caused this

Third Amendment to Distribution Agreement to be executed by their duly authorized representatives as of the Third Amendment Date.

FRESENIUS MEDICAL CARE HOLDINGS, INC.

By:

/s/

Patricia Rich

Name: Patricia Rich

Title: Sr. Vice President and Secretary

Date: April 9, 2026

HUMACYTE, INC.

By:

/s/ Dale Sander

Name: Dale Sander

Title: Chief Financial Officer

Date: April 21, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2612631d1_ex99-1.htm · Sequence: 3

Exhibit 99.1

Humacyte

Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

- Ex-U.S. rights realigned under amendment to

distribution agreement with Fresenius Medical Care -

- Positions Humacyte to advance discussions

with corporate partners regarding international and indication-specific rights to Symvess –

- Existing terms related to U.S. distribution

of Symvess remain unchanged

DURHAM, N.C., April 24, 2026 – Humacyte, Inc.

(Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial

scale, today announced that it has realigned the ex-U.S. rights to Symvess (acellular tissue engineered vessel) through an amendment to

its distribution agreement with Fresenius Medical Care (FME).

““We are pleased to have worked successfully with our long-time

partner and largest shareholder Fresenius Medical Care, to realign the global rights to Symvess in a manner that benefits both companies

and best enables Humacyte’s planned international expansion,” said Dr. Laura Niklason, CEO of Humacyte. “The restructuring

of ex-U.S. commercial rights enables us to fully advance the commercial initiatives that we previously announced in the Kingdom of Saudi

Arabia and Israel in vascular injury repair and other indications. In addition, we are now positioned to advance discussions with prospective

corporate partners regarding international and indication-specific rights to Symvess. As amended, the distribution agreement now provides

that Humacyte will have the exclusive rights to distribute Symvess outside the U.S., and FME will be entitled

to low-single-digit royalties on our net sales of Symvess outside the U.S. Existing terms related to the U.S. remain unchanged.”

For uses other than the FDA approval in the extremity vascular trauma

indication, Symvess is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology

platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve

the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide

range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered

vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage

clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease

(PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes,

and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate

to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation.

Humacyte’s 6mm ATEV for urgent arterial repair following

extremity vascular trauma and for advanced PAD also have received

RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For

more information, visit www.Humacyte.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based

on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following

words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,”

“plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,”

“potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology,

although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that

may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or

implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained

in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and

our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not

limited to, our plans and ability to commercialize Symvess (including commercial initiatives in the Kingdom of Saudi Arabia and Israel)

and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market

acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our

product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient

quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives;

our plans and ability to execute product development, process development and preclinical development efforts successfully and on our

anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates

and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our

ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected

benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that

adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that

the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number

of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others,

changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive

and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors”

in our Annual Report on Form 10-K for the year ended December 31, 2025 filed by Humacyte with the SEC, and in future SEC filings.

Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements

prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements,

you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and

plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking

statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of

any date subsequent to the date of this press release.

Humacyte Investor Contact:

Joyce Allaire

LifeSci Advisors LLC

+1-617-435-6602

jallaire@lifesciadvisors.com

investors@humacyte.com

Humacyte Media Contact:

Rich Luchette

Precision Strategies

+1-202-845-3924

rich@precisionstrategies.com

media@humacyte.com

GRAPHIC

Filename: tm2612631d1_ex99-1img001.jpg · Sequence: 8

Binary file (7873 bytes)

Download tm2612631d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 10

v3.26.1

Cover

Apr. 21, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 21, 2026

Entity File Number

001-39532

Entity Registrant Name

Humacyte, Inc.

Entity Central Index Key

0001818382

Entity Tax Identification Number

85-1763759

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2525 East North Carolina Highway 54

Entity Address, City or Town

Durham

Entity Address, State or Province

Entity Address, Postal Zip Code

27713

City Area Code

919

Local Phone Number

313-9633

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock [Member]

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

HUMA

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 [Member]

Title of 12(b) Security

Redeemable

Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

Trading Symbol

HUMAW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=HUMA_RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: